Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more
Vectus Biosystems Ltd (VBS) - Total Assets
Latest total assets as of June 2025: AU$782.66K AUD
Based on the latest financial reports, Vectus Biosystems Ltd (VBS) holds total assets worth AU$782.66K AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vectus Biosystems Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vectus Biosystems Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Vectus Biosystems Ltd's total assets of AU$782.66K consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 32.1% |
| Accounts Receivable | AU$437.57K | 55.9% |
| Inventory | AU$978.00 | 0.1% |
| Property, Plant & Equipment | AU$4.22K | 0.5% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vectus Biosystems Ltd's current assets represent 99.5% of total assets in 2025, an increase from 58.8% in 2012.
- Cash Position: Cash and equivalents constituted 32.1% of total assets in 2025, down from 50.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 55.9% of total assets.
Vectus Biosystems Ltd Competitors by Total Assets
Key competitors of Vectus Biosystems Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vectus Biosystems Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Vectus Biosystems Ltd generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vectus Biosystems Ltd is currently not profitable relative to its asset base.
Vectus Biosystems Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 3.45 | 2.02 |
| Quick Ratio | 0.93 | 3.45 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 1.86 |
| Working Capital | AU$-57.45K | AU$ 1.31 Million | AU$ 1.47 Million |
Vectus Biosystems Ltd - Advanced Valuation Insights
This section examines the relationship between Vectus Biosystems Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.66 |
| Latest Market Cap to Assets Ratio | 2.58 |
| Asset Growth Rate (YoY) | -61.4% |
| Total Assets | AU$782.66K |
| Market Capitalization | $2.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vectus Biosystems Ltd's assets at a significant premium ( 2.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vectus Biosystems Ltd's assets decreased by 61.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual total assets of Vectus Biosystems Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$782.66K | -61.36% |
| 2024-06-30 | AU$2.03 Million | -56.25% |
| 2023-06-30 | AU$4.63 Million | +17.62% |
| 2022-06-30 | AU$3.94 Million | -43.60% |
| 2021-06-30 | AU$6.98 Million | +132.77% |
| 2020-06-30 | AU$3.00 Million | +1444.61% |
| 2019-06-30 | AU$194.11K | -1.11% |
| 2018-06-30 | AU$196.28K | -72.76% |
| 2017-06-30 | AU$720.55K | -84.62% |
| 2016-06-30 | AU$4.68 Million | -60.06% |
| 2015-06-30 | AU$11.73 Million | +1533.55% |
| 2014-06-30 | AU$717.98K | -51.88% |
| 2013-06-30 | AU$1.49 Million | +121.75% |
| 2012-06-30 | AU$672.80K | -- |